New Drug R&D

Science-Driven, Life Forward

Our Company

Company Overview

AU-funded enterprise: Xiangbei Wellman holds 75% and Macau investors hold 25%

R&D Directions

Innovative drug R&D for metabolic diseases, oncology, neuropsychiatric disorders, antibiotic-resistant bacteria, and erectile dysfunction

Development Plan

Built a full R&D pipeline from drug molecular design to commercialization

Equity Structure

Xiangbei Wellman 75% | Macau Investors 25%

Research Collaboration

Developing innovative drugs for the global market through deep collaboration with renowned universities.

Macau University of Science and Technology

Collaborative innovative drug development

China Pharmaceutical University

Pharmaceutical R&D collaboration

Sun Yat-sen University

Industry-Academia-Research Collaboration

Global Layout

Leveraging the geographic advantages of the Hengqin Guangdong-Macao In-Depth Cooperation Zone to develop innovative drugs for the global market

Core Product Pipeline

Focus on major disease areas to develop globally competitive innovative drugs

Focus on major disease areas to develop globally competitive innovative drugs

F-02-2-Na

Indication

Gout / Hyperuricemia

Mechanism

URAT1 Inhibitor

Development Stage

IND approved in China and the U.S. (August 2025)

Anti-Cancer Drug

Indication

Glioma

Mechanism

Overcome drug resistance

Development Stage

PCC stage; IND filing expected 2026

XCY-A-006-a31

Indication

Insomnia

Mechanism

Orexin Receptor (OXR)

Development Stage

PCC stage